Results of New Meta-Analysis Further Demonstrate Safety Profile and Robust Efficacy of EndoBarrier® Therapy in Patients with Type 2 Diabetes and Obesity
GI Dynamics Announces EndoBarrier® Therapy Data to be Presented at International Diabetes Foundation World Diabetes Conference
GI Dynamics Announces EndoBarrier® Therapy Data to be Presented at Obesity Week
EndoBarrier® is indicated to treat patients with type 2 diabetes and/or obesity for 12 months.
EndoBarrier® has received regulatory approval and is commercially available for use in select international markets.
EndoBarrier® is not approved for sale in the United States and is considered investigational.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE